Travatrelvir, an Inhibitor of SARS CoV 2 Main Protease now in Phase 1 Clinical Trials: in vitro Drug Resistance Compared to Nirmatrelvir
356V Travatrelvir, an Inhibitor of SARS-CoV-2 Main...
Source: marketscreener.com
📰 Genscript Inc News
Genscript Inc News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Genscript Inc. Real-time updates on events, politics, business and more.
GenScript Debuts AmMag™ Quatro to Revolutionize Automated Plasmid Maxi-Prep Purification
Latest innovative laboratory automation technology from GenScript is set to streamline maxi-scale plasmid purification, significantly reducing the manpower and time required to obtain high-quality,... | June 20, 2023
Source: marketscreener.com
Biodesix to Participate in Two Upcoming Investor Conferences in September
BOULDER, Colo.--(BUSINESS WIRE)--$BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will participate in two upcoming investor conferences:Morgan Stanley 20th Annual Gl...
Source: pharmiweb.com
Royal Philips: Philips incorporates Biodesix blood-based proteomic nodule risk assessment testing into Lung Cancer Orchestrator to advance early lung cancer diagnosis
June 30, 2022Solution adds proteomic analysis of blood-based biomarkers to Philips Lung Cancer Orchestrator to better assess the risk of lung nodule malignancy, enhancing decision-making for diagnosis
Source: finanznachrichten.de
Biodesix to Present at the 42nd Annual William Blair Growth Stock Conference
01.06.2022 - Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will present at the 42nd Annual William Blair Growth Stock Conference ...
William Blair Genscript Inc Nodify Lung Diagnostic Cortex Artificial Intelligence Pass Neutralization Test Kit
Source: wallstreet-online.de
Biodesix Announces First Quarter 2022 Results and Highlights
11.05.2022 - Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced its financial and operating results for first quarter ended March 31, 2022 and provided a corporate update. “We are ...
Source: wallstreet-online.de
Biodesix Announces Fourth Quarter and Year End 2021 Results and Highlights
Fourth Quarter and Fiscal Year 2021 Lung Diagnostic Revenue of $5.4 Million and $18.7 Million Increased 48% and 49% over the comparable 2020 periods, respectively Full-Scale Launch of GeneStrat... | March 14, 2022
Source: marketscreener.com
Biodesix Announces Common Stock Purchase Agreement for up to $50 Million with Lincoln Park Capital
BOULDER, Colo.--(BUSINESS WIRE)--$BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced it has entered into a purchase agreement for the issuance and sale of its common stock, from time to time, of up to $50 million with L...
Source: pharmiweb.com
Biodesix to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
BOULDER, Colo.--(BUSINESS WIRE)--$BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will present in a fireside chat at the BTIG MedTech, Digital Health, Life Science &...
Source: pharmiweb.com
Biodesix Announces Appointment of Successful Innovator and Scientific Professional Jon Faiz Kayyem, PhD to Board of Directors
Dr. Kayyem’s diverse career spans more than 20 years and includes experience in academia, lean startups, and Fortune 100 companies.
Scott Hutton Jon Faiz Kayyem Yale University Life Sciences At Motorola Efficacy Capital Biodesix Inc
Source: pressreleasepoint.com